TNFSF10 and malignant colon neoplasm: Furthermore, TRAIL-iron oxide NPs induced ROS-mediated JNK activation, which in turn, could support DR5 up-regulation, and subsequently promoted antitumor efficacy of TRAIL in TRAIL-resistant colon cancer HT-29, intermediately resistant SW-480 and sensitive HCT-116 cells, in vitro.